Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III secukinumab in anti-TNF inadequate responder rheumatoid arthritis
jRCT2080222045Phase 3
- Sponsor
- Novartis
- Start
- Mar 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in rheumatoid arthritis (RA) (3 arms), sponsored by Novartis. Primary endpoint: Efficacy at 24 weeks.
02
Drugs
secukinumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2080222045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222045.